key: cord-0916555-vi8ywy79
authors: Goyal, Abhishek; Saxena, Khushboo; Kar, Avishek; Khurana., Alkesh; Kaur Bhagtana, Parneet; Siva Koti Rupa Sridevi, Chinta; Pakhare., Abhijit
title: Obstructive sleep apnea is highly prevalent in COVID19 moderate to severe ARDS survivors: Findings of level I Polysomnography in a tertiary care hospital()
date: 2021-06-19
journal: Sleep Med
DOI: 10.1016/j.sleep.2021.06.015
sha: 1a8a32c2978dff66aceabbbea056e5412874619e
doc_id: 916555
cord_uid: vi8ywy79

STUDY OBJECTIVES: Studies have found Obstructive Sleep Apnea (OSA) as a risk factor for increased risk for COVID19 Acute respiratory Distress Syndrome (ARDS); but most of the studies were done in already known patients of OSA. This study was done to find prevalence of OSA in patients with COVID-19 related acute respiratory distress syndrome. METHODOLOGY: A hospital based longitudinal study was conducted among COVID 19 Intensive Care Unit (ICU) survivors. All consecutive COVID19 with moderate to severe ARDS were evaluated for OSA by Level I Polysomnography (PSG) after 4-6 weeks of discharge. Prevalence of OSA and PSG variables {Total sleep time, Sleep efficiency, sleep stage percentage, Apnea Hypopnea Index (AHI), T90, nadir oxygen} was estimated. RESULTS: Out of 103 patients discharged from ICU during study period (October 2020 to 15 December 2020), 67 underwent Level I PSG. Mean Age was 52.6±10.9 years and mean Body Mass Index was 27.5 ± 6.2 Kg/m(2). Total sleep time was 343.2 ± 86 minutes, sleep efficiency was 75.9±14.2%. OSA (AHI ≥5) was seen in 65/67 patients and 49 patients had moderate to severe OSA (i.e. AHI ≥ 15). CONCLUSION: Moderate-severe OSA was highly prevalent (73%) in COVID19 moderate to severe ARDS survivors. Role of OSA in pathophysiology of COVID19 ARDS needs further evaluation.

COVID-19 has been one of the biggest catastrophe in the history of mankind Till date 100 million people have been infected and more than 2 million have died of this infection.

Severity of COVID-19 infection has been attributed to several comorbid conditions like systemic hypertension, diabetes mellitus, coronary artery disease and chronic kidney disease. 1 In an attempt to decipher the pathophysiology and predisposing conditions, researchers are exploring newer avenues . Published articles have also assessed Obstructive Sleep Apnea(OSA) as a probable risk factor for severe COVID-19 disease due to shared pathophysiological pathways. 2,3 A retrospective study which was based on electronic health record has identified OSA as risk factor for mortality in COVID19 ARDS. 4 Moreover the relationship of severity of OSA with that of COVID-19 has not been precisely documented.

This study was done to find prevalence of OSA in patients with COVID-19 related moderate to severe Acute respiratory distress syndrome.

This is a single centred prospective study conducted at a tertiary care teaching hospital in India. This study was carried over a period of two months (October 2020 to December 2020) on consecutive symptomatic COVID19 related acute respiratory distress syndrome patients who were discharged from ICU or isolation wards.

Aim of this study was to find prevalence of OSA in patients with COVID- 5. Patients must have tested negative COVID 19 (nasopharyngeal swab-RT PCR) at least 3 weeks prior to study 

Discussion: This study shows that OSA is highly prevalent in patients with COVID19 induced ARDS. To the best of our knowledge, it is first study in which level I PSG was done in COVID19 survivors.

Breathing disruption seen in OSA is associated with sympathetic activity surge and hypoxemia which predisposes patients to cardiovascular and neurological complications. 8, 9, 10 OSA has been associated with obesity, hypertension, Diabetes Mellitus (DM), Coronary artery disease, arrythmia, nocturia, chronic kidney disease, dyslipidaemia, metabolic syndrome, and pulmonary embolism. 8, 11, 12 Association of COVID 19 ARDS is now known with various risk factors like obesity, older age, male sex, DM, hypertension, Coronary Artery Disease and Chronic Kidney Disease. 13 Most important of these factors were age, obesity, and DM; all these three factors are closely interlinked with OSA. SARS CoV2 enters cells through Angiotensin Converting Enzyme-2 receptors in lungs and there is increased expression of these receptors in obese individuals. 14 OSA might precipitate inflammation caused due to COVID19 by multiple pathways: OSA itself leads to hypoxemia and hypoventilation during sleep and superimposed COVID19 can lead to profound hypoxemia. 15 Studies have shown increased inflammatory markers (like IL6 and CRP) in patients with OSA. 16, 17 OSA is a known risk factor for cardiac complications (hypertension, heart failure, acute cardiovascular events & arrhythmias) and thus may increase cardiac morbidity and mortality in patients when they contract COVID infection. 8, 11, 12 DVT and PE risks were shown to be 3.50-and 3.97-fold higher respectively in OSA cohort than in the reference cohort. 18 Hemodynamic alterations in OSA lead to J o u r n a l P r e -p r o o f polycythaemia and sluggish blood flow, which can possibly lead to procoagulant state. 19, 20, 21 This hypercoagulable state can probably further increase risk for COVID related coagulopathy.

Recently few studies have tried to find out possibility of poor outcome in COVID19 with pre-existing OSA. In an electronic health record review, mortality was found to be much higher in patients with known OSA (11.7%) compared to controls (6.9%) with an odds ratio of 1.7923. 4 (correlating with moderate-severe OSA) were found to independent effect on mortality.

In all previous done work, association with severity of COVID19 was tried to be found in already known patients of OSA. But it is a known fact that more than 90% of patients with OSA remain undiagnosed. 24 None of patients (in current study) were ever evaluated for OSA before COVID19 infection and yet 73% of them had moderate-severe OSA.

In pre-COVID19 era, very few studies were done to evaluate sleep disorders (with level I PSG) in ARDS survivors. In a study done from J o u r n a l P r e -p r o o f India, PSG was done in 20 ARDS survivors after 4 weeks of discharge from ICU: 2 had Central Sleep Apnea and one had OSA. 25 In another study from United Kingdom, level I PSG was done immediately after discharge from ICU; out of 15 mechanically ventilated patients, 11 had OSA (AHI≥5) and 9 (60%) had Moderate-severe OSA (AHI≥15). 26 In another study, seven ARDS survivors without previous sleep complaints reported difficulty sleeping 6 months after discharge from hospital. 27 All these seven patients underwent PSG and only one had apnea. Further, N3 and REM sleep was significantly reduced, which was consistent with previous reports.

The high prevalence of OSA seen in patients with COVID19 ARDS in our study hints that OSA might be an independent risk factor for poor prognosis in patients with COVID19. To prove this however, PSG should be done in asymptomatic or minimally symptomatic individuals diagnosed with COVID19.

Untreated OSA can lead to cardiac complications and persistent symptoms including fatigability, insomnia, which are commonly seen in followup of COVID`19 patients. 28 So in our opinion OSA should be ruled out in COVID19 ARDS survivors with these complaints and if moderatesevere OSA is present, it should be treated with Continuous Positive Airway Pressure (CPAP) therapy. 29, 30 Most important strength of this study is that gold standard level I PSG was done in consecutive ICU survivors. To the best of our knowledge, this is the first study in which PSG was done in COVID19 patients. Although our previous work have shown increased mortality among those with high risk for OSA (as assessed with OSA screening questionnaires). 23 2) Association between presence of OSA and severity of COVID19 could not be explored owing to inclusion of participants from only ICU.

For this, patients with minimal or mild symptoms of COVID19 should have been included in study. However due to resource constraints, we restricted our study to ICU survivors. Participants of this study were patients from ICU only therefore findings should not be generalised to all COVID19 patients.

To summarise, moderate-severe OSA is highly prevalent (73%) in COVID19 moderate to severe ARDS survivors and it will be interesting to explore further effect of role of OSA in pathophysiology of COVID19 ARDS.

We want to thank Mr Amit Sen, Mr Chetan, Mr Ranjit and Ms Artee for performing polysomnography.

AG: Conceptualized, data collection, analysis, patient management and manuscript writing. KS: Data collection, Patient management, manuscript writing Av K: Patient management, Data collection, manuscript writing AK: Patient management, Manuscript writing PKB: Data collection, manuscript writing CSKRS: Data collection, manuscript writing AP: Analysis, manuscript writing Compliance with Ethical Standards: This is a retrospective analysis study and waiver of this study was taken from ethical clearance committee. 

Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China

OSA as a probable risk factor for severe COVID-19

COVID 19 and OSA: exploring multiple cross-ways

American journal of respiratory and critical care medicine. NLM (Medline); 2020

Rules for scoring respiratory events in sleep: update of the 2007 AASM Manual for the Scoring of Sleep and Associated Events. Deliberations of the Sleep Apnea Definitions Task Force of the American Academy of Sleep Medicine

R: A Language and Environment for Statistical Computing

Austria: R Foundation for Statistical Computing

Presentation-Ready Data Summary and Analytic Result Tables

Cardiovascular and metabolic effects of CPAP in obese males with OSA

Association of pediatric obstructive sleep apnea with poor academic performance: A school-based study from India

Association of Sleep Disordered Breathing with Mono-Symptomatic Nocturnal Enuresis: A Study among School Children of Central India

Nocturic obstructive sleep apnea as a clinical phenotype of severe disease

Women with OSA have higher chances of having metabolic syndrome than men: effect of gender on syndrome Z in cross sectional study

The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system

Obesity and COVID-19: ACE 2, the Missing Tile

Diagnosing obstructive sleep apnea patients with isolated nocturnal hypoventilation and defining obesity hypoventilation syndrome using new European Respiratory Society classification criteria: an Indian perspective

Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation

Elevated tau and interleukin-6 concentrations in adults with obstructive sleep apnea

Association between obstructive sleep apnea and deep vein thrombosis / pulmonary embolism: a population-based retrospective cohort study

Does obstructive sleep apnea increase hematocrit? Sleep Breath

Is obstructive sleep apnoea syndrome really one of the causes of secondary polycythaemia? Hematology

Successful use of tPA for thrombolysis in COVID related ARDS: a case series

Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study

Association of Obstructive Sleep Apnea and severity of COVID-19: A hospital based observational study. medRxiv

Increased Prevalence of Sleep-Disordered Breathing in Adults

Sleep after critical illness: Study of survivors of acute respiratory distress syndrome and systematic review of literature

Sleep-related breathing disorders following discharge from intensive care

Chronic sleep disorders in survivors of the acute respiratory distress syndrome

Sleep Neurologists Call It 'COVID-Somnia'-Increased Sleep Disturbances Linked to the Pandemic

Clinical Guidelines for the Manual Titration of Positive Airway Pressure in Patients with Obstructive Sleep Apnea